Tredje AP fonden Makes New $12.61 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

Tredje AP fonden acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 16,330 shares of the biopharmaceutical company’s stock, valued at approximately $12,605,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Dodge & Cox grew its holdings in shares of Regeneron Pharmaceuticals by 18.9% during the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after acquiring an additional 724,562 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 528.7% during the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock valued at $405,596,000 after acquiring an additional 606,612 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 38.0% during the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after acquiring an additional 408,649 shares in the last quarter. Caisse de depot et placement du Quebec grew its holdings in shares of Regeneron Pharmaceuticals by 115.4% during the 3rd quarter. Caisse de depot et placement du Quebec now owns 462,502 shares of the biopharmaceutical company’s stock valued at $260,051,000 after acquiring an additional 247,780 shares in the last quarter. Finally, Man Group plc grew its holdings in shares of Regeneron Pharmaceuticals by 257.6% during the 3rd quarter. Man Group plc now owns 271,707 shares of the biopharmaceutical company’s stock valued at $152,773,000 after acquiring an additional 195,724 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

REGN has been the topic of several research analyst reports. Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a report on Friday, May 1st. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $792.65.

Regeneron Pharmaceuticals Stock Up 0.1%

REGN stock opened at $630.30 on Wednesday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a fifty day simple moving average of $739.39 and a 200 day simple moving average of $745.76. The firm has a market cap of $66.64 billion, a PE ratio of 15.36, a PEG ratio of 1.40 and a beta of 0.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the previous year, the business earned $8.22 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.1 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron announced a strategic collaboration with Parabilis Medicines to develop novel Antibody-Helicon Conjugates across multiple therapeutic areas, a deal that could be worth up to about $2.2 billion in milestone payments plus royalties and expands REGN’s pipeline into “undruggable” targets. Article: Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
• Positive Sentiment: Several analysts still maintained constructive views on REGN despite trimming price targets, including buy/overweight calls from firms such as Canaccord, JPMorgan, Piper Sandler, BMO, and Wells Fargo, suggesting Wall Street still sees meaningful upside from current levels.
• Neutral Sentiment: Regeneron’s latest earnings backdrop remains solid, with Q1 revenue up 19% year over year and results that beat consensus estimates, helping offset some of the pressure from recent headlines.
• Negative Sentiment: The main driver of the stock’s weakness was a late-stage melanoma trial failure: fianlimab plus cemiplimab did not meet its primary progression-free survival endpoint versus Merck’s Keytruda, raising questions about the company’s near-term oncology growth prospects. Article: Regeneron drops after skin cancer treatment misses late-stage trial goal
• Negative Sentiment: The trial miss triggered multiple analyst price-target cuts and a wave of shareholder-investigation headlines, adding to sentiment pressure and keeping attention on execution risk in REGN’s pipeline.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.